MP07-09 12-MONTH ANALYSIS OF ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN: SUSTAINED OXALATE LOWERING AND KIDNEY STONE EVENT RATES IN PRIMARY HYPEROXALURIA TYPE 1

INTRODUCTION AND OBJECTIVE:ILLUMINATE-A is a Phase 3 trial of lumasiran, an RNAi therapeutic indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in ped...